Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ethiodan
2. Iodophendylate
3. Ioglunide
4. Iophendylate
5. Isophendylate
6. Maiodil
7. Myodil
8. Panthopaque
9. Pantopaque
1. Ethyl 10-(4-iodophenyl)undecanoate
2. 99-79-6
3. Iofendylatum
4. Ethyl 10-(p-iodophenyl)undecylate
5. Ethyl 10-(p-iodophenyl)hendecanoate
6. 6v3i57k9ul
7. Jofendylatum
8. Iophendylate, P-
9. Ethiodan
10. Mulsopaque
11. Neurotrast
12. Myodil
13. Myodyl
14. Mulsopaque; Myodil; Myodyl; Neurotrast; Pantopaque
15. Iofendilato
16. P-iophendylate
17. Iofendylatum [inn-latin]
18. Iofendilato [inn-spanish]
19. Hsdb 3346
20. Ethyl 10-(p-iodophenyl)undecanoate
21. Iofendylate [inn:ban]
22. Einecs 202-787-8
23. Brn 2661373
24. Unii-6v3i57k9ul
25. Iophendilate
26. Undecanoic Acid, 10-(p-iodophenyl)-, Ethyl Ester
27. Jofendylate
28. Benzenedecanoic Acid, 4-iodo-iota-methyl-, Ethyl Ester
29. Iophendylate [mi]
30. Chembl951
31. 3-09-00-02627 (beilstein Handbook Reference)
32. Schembl492663
33. Dtxsid2052869
34. Ethyl10-(4-iodophenyl)undecanoate
35. Hy-a0223
36. Akos005267217
37. Cs-0017569
38. Ft-0682962
39. Q3801357
40. W-100019
41. Benzenedecanoic Acid, 4-iodo-.iota.-methyl-, Ethyl Ester
| Molecular Weight | 416.3 g/mol |
|---|---|
| Molecular Formula | C19H29IO2 |
| XLogP3 | 7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 12 |
| Exact Mass | 416.12123 g/mol |
| Monoisotopic Mass | 416.12123 g/mol |
| Topological Polar Surface Area | 26.3 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 285 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Contrast Media
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
IT IS ABSORBABLE, IODIZED FATTY ACID COMPD OF LOW VISCOSITY DESIGNED ESPECIALLY FOR MYELOGRAPHY. ... IT IS EQUALLY USEFUL FOR VISUALIZATION OF ALL REGIONS OF SPINAL CORD, ALTHOUGH THIS MAY BE TECHNICALLY MORE DIFFICULT IN CERVICAL & THORACIC REGIONS. ... IOPHENDYLATE ALSO IS USED IN EMULSIFIED AQUEOUS FORM AS CONTRAST MEDIUM FOR VISUALIZATION OF BILIARY TREE, SINUS TRACTS, & CERTAIN BODY CAVITIES.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 802
IT IS COMMONLY USED FOR VISUALIZATION OF TUMORS OR HERNIATION OF INTERVERTEBRAL DISC OR OTHER LESIONS COMPRESSING SPINAL CORD.
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 1215
VET: TO OUTLINE SALIVARY GLANDS, DRAINING SINUSES, OR FISTULAS; IT MAY BE SAFE (1-3 ML) IN SPINAL VENTRICULOGRAPHY OF DOGS.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 285
DOSE- USUAL, MYELOGRAPHY, INTRATHECAL OR BY SPECIAL INJECTION
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 1215
THIS AGENT SHOULD NOT BE USED INTRAVASCULARLY. ... AGENT SHOULD NOT BE USED WHEN LUMBAR PUNCTURE IS CONTRAINDICATED; &, TO AVOID SUBDURAL & EXTRA-ARACHNOID EXTRAVASATION, IT SHOULD NOT BE EMPLOYED WITHIN 10 DAYS OF PREVIOUS LUMBAR PUNCTURE.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 802
...PERSISTENT LEVELS IN BODY INTERFERE WITH TRACER STUDIES WITH RADIOACTIVE IODINE.
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 1215
WHEN BULK OF MATERIAL IS REMOVED...INCIDENCE OF SIDE REACTIONS IS LOW.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 802
IN GENERAL, IODINATED CONTRAST MEDIA SHOULD BE ADMINISTERED WITH CAUTION IN PATIENTS WITH HEPATIC OR RENAL DYSFUNCTION. ... THE INJECTION OF IODIZED FATTY ACIDS IS ESSENTIALLY A SURGICAL PROCEDURE THAT INVOLVES RISK. THE FOLLOWING CAUTIONS SHOULD BE BORNE IN MIND. PREPARATIONS THAT HAVE AGED & DARKENED BEYOND THE ORIGINAL COLOR SHOULD NOT BE USED. ... THE COMPOUNDS SHOULD NOT BE ADMINISTERED TO INDIVIDUALS WITH HISTORY OF SENSITIVITY TO IODIDES. /IODINATED CONTRAST MEDIA/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 803
For more Drug Warnings (Complete) data for IOPHENDYLATE (6 total), please visit the HSDB record page.
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
V - Various
V08 - Contrast media
V08A - X-ray contrast media, iodinated
V08AD - Non-watersoluble x-ray contrast media
V08AD04 - Iofendylate
WHEN EXAM IS COMPLETED, COMPD SHOULD BE REMOVED BY ASPIRATION. WHEN BULK OF MATERIAL IS REMOVED, REMAINDER IS ABSORBED WITHIN FEW MONTHS...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 802
ABOUT THIS PAGE
87
PharmaCompass offers a list of Iophendylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Iophendylate manufacturer or Iophendylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Iophendylate manufacturer or Iophendylate supplier.
PharmaCompass also assists you with knowing the Iophendylate API Price utilized in the formulation of products. Iophendylate API Price is not always fixed or binding as the Iophendylate Price is obtained through a variety of data sources. The Iophendylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Iophendylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Iophendylate, including repackagers and relabelers. The FDA regulates Iophendylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Iophendylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Iophendylate supplier is an individual or a company that provides Iophendylate active pharmaceutical ingredient (API) or Iophendylate finished formulations upon request. The Iophendylate suppliers may include Iophendylate API manufacturers, exporters, distributors and traders.
Iophendylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Iophendylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Iophendylate GMP manufacturer or Iophendylate GMP API supplier for your needs.
A Iophendylate CoA (Certificate of Analysis) is a formal document that attests to Iophendylate's compliance with Iophendylate specifications and serves as a tool for batch-level quality control.
Iophendylate CoA mostly includes findings from lab analyses of a specific batch. For each Iophendylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Iophendylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Iophendylate EP), Iophendylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Iophendylate USP).
